CX 2026 Registration
CX Executive Board
CX 2026 Programme
CX 2026 – The 48th Charing Cross Symposium
The Charing Cross (CX) Symposium continues to set the standard in vascular and endovascular education, shaping the future of practice worldwide. CX 2026 marked the final chapter of our current three-year cycle, designed to spark debate on the biggest controversies in the field. Our distinguished faculty of global experts critically examined the evidence, exchanged perspectives, and worked towards building consensus on the issues that matter most.
Consensus was the defining theme for CX 2026. We welcomed an international community of specialists, educators, and innovators to tackle the pressing challenges in vascular and endovascular medicine—challenges that directly impact patient outcomes and clinical decision-making.
In 2024, CX found a new home at ExCeL London, unlocking fresh opportunities for immersive, hands-on learning. The expanded workshop programme has gone from strength to strength, offering delegates practical skills alongside groundbreaking evidence and innovation. In 2026, we returned once again to London’s premier conference and exhibition venue to deliver an agenda packed with cutting-edge science, expert debate, and future-shaping education.
Stay connected—sign up for the CX Newsletter and be the first to hear the latest updates.
CX Co-Chairs
Latest CX news
CX 2019: NICE AAA guidelines under the spotlight
The publication of the draft aortic guidelines by the National Institute for Health and Care Excellence (NICE) in May 2018 raised quite a stir. However, the story is not over. In a CX Special [...]
CX 2019: Vascular EDUCATION as it should be
CX is Europe’s largest and longest-running vascular symposium and delivers vascular EDUCATION as it should be CX raises CONTROVERSIES, CHALLENGES the evidence to reach CONSENSUS in a three yearly cycle after discussion involving a world-class faculty and expert audience. [...]
CX 2019: The last word on the paclitaxel controversy
Since the publication of Katsanos et al's meta-analysis in the Journal of the American Heart Association (JAHA), the science and support for paclitaxel-releasing devices in the legs is an unfolding story. A CX 2019 [...]